Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
Hemogenyx Pharmaceuticals Announces Strategic Investment from Prevail Partners, LLC
Tuesday, September 19, 2023Hemogenyx Pharmaceuticals plc LSE HEMO the biopharmaceutical group developing new therapies and treatments for blood diseases announces that Prevail Partners LLC Prevail Partners an investment fund has agreed to invest in the Company through a subscr...
Medigene AG Announces Lead Selection for MDG2011 Representing the First TCR-T Therapy of its KRAS Library
Tuesday, September 19, 2023Medigene AG Medigene the Company FSE MDG Prime Standard an immunooncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors announces today that it has selected its lead candidate for MDG
Orchard Therapeutics Announces Acceptance of Biologics License Application for OTL-200 in MLD and Receives Priority Review
Monday, September 18, 2023Orchard Therapeutics Nasdaq ORTX a global gene therapy leader today announced the US Food and Drug Administration FDA has accepted the filing of its Biologics License Application BLA for OTL in metachromatic leukodystrophy MLD under Priority Review
GenScript Expands Range of Reagent Services, Adding Circular RNA and Lipid Nanoparticles Formulation
Monday, September 18, 2023GenScript Biotech Corporation the worlds leading provider of lifescience research tools and services has expanded its IVT mRNA synthesis portfolio with the addition of customized circular RNA circRNA and lipid nanoparticles LNPs formulation services
Ascendis Pharma Launches SKYTROFA® (lonapegsomatropin) in Germany for the Once-Weekly Treatment of Children and Adolescents with Growth Hormone Deficiency
Saturday, September 16, 2023Ascendis Pharma AS Nasdaq ASND today announced the launch in Germany of SKYTROFA lonapegsomatropin its growth hormone approved in the European Union for the onceweekly treatment of children and adolescents ages to years with growth failure due to i...
ERS Genomics & Demeetra Enter Into CRISPR/Cas9 Licensing Agreement
Friday, September 15, 2023ERS Genomics Limited ERS is pleased to announce a new license agreement with Demeetra AgBio Demeetra This is a nonexclusive licensing agreement granting Demeetra access to the ERS CRISPRCas patent portfolio which is sublicensable when combined with C...
Anavex’s Phase 2b/3 Trial of Blarcamesine (ANAVEX®2-73) in Patients with Alzheimer’s Disease Shows Robust Clinical Efficacy and Slows Neurodegeneration
Friday, September 15, 2023Anavex Life Sciences Corp Anavex or the Company Nasdaq AVXL a clinicalstage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders announced today that a followon analy...
Ocugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)
Thursday, September 14, 2023Ocugen Inc Ocugen or the Company NASDAQ OCGN a biotechnology company focused on discovering developing and commercializing novel gene and cell therapies biologics and vaccines
Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart (formerly ADX-914) for Severe Alopecia Areata
Thursday, September 14, 2023Q Bio a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis and Horizon Therapeutics plc Nasdaq HZNP today announced that the first patient has been dosed in a randomized doubleblind placebocontrolled
Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK® for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma
Wednesday, September 13, 2023Affimed NV Nasdaq AFMD Affimed or the Company a clinicalstage immunooncology company committed to giving patients back their innate ability to fight cancer today announced that the FDA has granted fast track designation to the combination of its inna...
